



Clinical trial results:

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Summary

EudraCT number	2015-000990-11
Trial protocol	DK SE GB AT CZ ES FI PT BE NL FR DE LT PL GR RO IE SK IT
Global end of trial date	14 April 2020

Results information

Result version number	v1 (current)
This version publication date	22 April 2021
First version publication date	22 April 2021

Trial information

Trial identification

Sponsor protocol code	16244
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02540993
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser Wilhelm Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 April 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 April 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) $\geq 40\%$ from baseline over at least 4 weeks, or renal death.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy:

Standard of care: individual maximum tolerated labeled dose of either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) (but not both)

Evidence for comparator: -

Actual start date of recruitment	17 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 62
Country: Number of subjects enrolled	Belgium: 54
Country: Number of subjects enrolled	Bulgaria: 225
Country: Number of subjects enrolled	Switzerland: 10
Country: Number of subjects enrolled	Czechia: 99
Country: Number of subjects enrolled	Germany: 88
Country: Number of subjects enrolled	Denmark: 111
Country: Number of subjects enrolled	Spain: 260
Country: Number of subjects enrolled	Finland: 62
Country: Number of subjects enrolled	France: 64
Country: Number of subjects enrolled	United Kingdom: 67
Country: Number of subjects enrolled	Greece: 48
Country: Number of subjects enrolled	Hungary: 140
Country: Number of subjects enrolled	Ireland: 5

Country: Number of subjects enrolled	Italy: 206
Country: Number of subjects enrolled	Lithuania: 9
Country: Number of subjects enrolled	Netherlands: 72
Country: Number of subjects enrolled	Norway: 26
Country: Number of subjects enrolled	Poland: 112
Country: Number of subjects enrolled	Portugal: 130
Country: Number of subjects enrolled	Romania: 59
Country: Number of subjects enrolled	Russian Federation: 263
Country: Number of subjects enrolled	Slovakia: 7
Country: Number of subjects enrolled	Sweden: 34
Country: Number of subjects enrolled	Turkey: 72
Country: Number of subjects enrolled	Ukraine: 73
Country: Number of subjects enrolled	Canada: 107
Country: Number of subjects enrolled	Puerto Rico: 13
Country: Number of subjects enrolled	United States: 824
Country: Number of subjects enrolled	China: 372
Country: Number of subjects enrolled	Hong Kong: 61
Country: Number of subjects enrolled	Israel: 252
Country: Number of subjects enrolled	Japan: 415
Country: Number of subjects enrolled	Korea, Republic of: 138
Country: Number of subjects enrolled	Malaysia: 77
Country: Number of subjects enrolled	Philippines: 45
Country: Number of subjects enrolled	Singapore: 19
Country: Number of subjects enrolled	Thailand: 36
Country: Number of subjects enrolled	Taiwan: 111
Country: Number of subjects enrolled	Vietnam: 53
Country: Number of subjects enrolled	Argentina: 84
Country: Number of subjects enrolled	Brazil: 176
Country: Number of subjects enrolled	Chile: 31
Country: Number of subjects enrolled	Colombia: 182
Country: Number of subjects enrolled	Mexico: 120
Country: Number of subjects enrolled	Australia: 63
Country: Number of subjects enrolled	New Zealand: 38
Country: Number of subjects enrolled	South Africa: 99
Worldwide total number of subjects	5674
EEA total number of subjects	1940

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2379
From 65 to 84 years	3252
85 years and over	43

Subject disposition

Recruitment

Recruitment details:

Study was conducted at multiple centers in 48 countries/regions between 17-SEP-2015 (first subject first visit) and 14-APR-2020 (last subject last visit).

Pre-assignment

Screening details:

Overall, 13911 subjects were screened. Of them, 8177 subjects were screening failures and 5734 subjects were randomized. 60 subjects were prospectively excluded from the analyses due to GCP violations resulting in 5674 subjects in the full analysis set. 16 subjects did not take any study drug resulting in 5658 subjects who received study treatment.

Period 1

Period 1 title	Analyzed (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Finerenone

Arm description:

Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy

Arm type	Experimental
Investigational medicinal product name	Finerenone
Investigational medicinal product code	BAY94-8862
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to < 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

Arm title	Placebo
------------------	---------

Arm description:

Subjects received matching placebo once daily in addition to standard of care therapy

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

Number of subjects in period 1	Finerenone	Placebo
Started	2833	2841
Treated	2827	2831 ^[1]
Completed	2824	2832
Not completed	9	9
Consent withdrawn by subject	4	6
Lost to follow-up	5	3

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Subjects were followed up regardless of having started treatment or not, and study completion (completion of period 1) is independent of administration of study treatment. A subject was considered as having completed the study if there was a contact with the subject after the end-of-study (EOS) notification or if the subject died.

Baseline characteristics

Reporting groups

Reporting group title	Finerenone
Reporting group description:	
Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo once daily in addition to standard of care therapy	

Reporting group values	Finerenone	Placebo	Total
Number of subjects	2833	2841	5674
Age Categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	65.44	65.67	-
standard deviation	± 8.94	± 9.16	-
Gender Categorical			
Units: Subjects			
Female	880	811	1691
Male	1953	2030	3983
Race			
Units: Subjects			
White	1777	1815	3592
Black or African American	140	124	264
Asian	717	723	1440
American Indian or Alaska Native	78	76	154
Native Hawaiian or Other Pacific Islander	11	7	18
Not Reported	9	10	19
Multiple	101	86	187
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	2376	2397	4773
Hispanic or Latino	447	431	878
Not Reported	10	13	23
Urinary albumin-to-creatinine ratio (UACR)			
Units: milligram/gram (mg/g)			
median	832.72	867.01	-
inter-quartile range (Q1-Q3)	441.00 to 1628.14	453.11 to 1644.58	-
Estimated glomerular filtration rate (eGFR)			
Units: mL/min/1.73m ²			
arithmetic mean	44.36	44.32	-
standard deviation	± 12.54	± 12.57	-

End points

End points reporting groups

Reporting group title	Finerenone
Reporting group description:	
Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo once daily in addition to standard of care therapy	
Subject analysis set title	Full analysis set (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
The FAS comprised all randomized subjects (except those with critical GCP violations)	

Primary: The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR $\geq 40\%$ from baseline over at least 4 weeks, or renal death

End point title	The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR $\geq 40\%$ from baseline over at least 4 weeks, or renal death
End point description:	
Count of subjects and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR $\geq 40\%$ from baseline over at least 4 weeks, or renal death were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.	
End point type	Primary
End point timeframe:	
From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months	

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2833	2841		
Units: Subjects				
number (not applicable)	504	600		

Statistical analyses

Statistical analysis title	Primary renal composite endpoint
Statistical analysis description:	
A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.	
Comparison groups	Finerenone v Placebo

Number of subjects included in analysis	5674
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0014 ^[1]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.825
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.732
upper limit	0.928

Notes:

[1] - P-value from stratified log-rank test. Significance was considered to be achieved if p-value ≤ 0.03282695.

Secondary: The first occurrence of the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure

End point title	The first occurrence of the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure
-----------------	---

End point description:

Count of subjects and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2833	2841		
Units: Subjects				
number (not applicable)	367	420		

Statistical analyses

Statistical analysis title	CV composite endpoint
-----------------------------------	-----------------------

Statistical analysis description:

A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.

Comparison groups	Finerenone v Placebo
-------------------	----------------------

Number of subjects included in analysis	5674
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0339 ^[2]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.747
upper limit	0.989

Notes:

[2] - P-value from stratified log-rank test. Significance was considered to be achieved if p-value ≤ 0.04967388.

Secondary: All-cause mortality

End point title	All-cause mortality
End point description:	
Count of subjects and time from randomization until death due to any cause were evaluated. Number of subjects with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis.	
End point type	Secondary
End point timeframe:	
From randomization up until death due to any cause, or censoring at the end of the study, with an average of 32 months	

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2833	2841		
Units: Subjects				
number (not applicable)	219	244		

Statistical analyses

Statistical analysis title	All-cause mortality
Statistical analysis description:	
A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.	
Comparison groups	Finerenone v Placebo
Number of subjects included in analysis	5674
Analysis specification	Pre-specified
Analysis type	superiority ^[3]
P-value	= 0.2348 ^[4]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.895

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.746
upper limit	1.075

Notes:

[3] - As treatment effect on both primary and key secondary endpoint was significant, other secondary efficacy endpoints (i.e. all-cause mortality, all-cause hospitalization, change in UACR from baseline to Month 4, and secondary renal composite endpoint) were tested hierarchically, starting with all-cause mortality. As treatment effect on all-cause mortality was not significant, all other endpoints were tested in an exploratory manner.

[4] - P-value from stratified log-rank test. Significance was considered to be achieved if p-value $\leq$ 0.04967388.

Secondary: All-cause hospitalization

End point title	All-cause hospitalization
-----------------	---------------------------

End point description:

Count of subjects and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of subjects with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of the study, with an average of 32 months

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2833	2841		
Units: Subjects				
number (not applicable)	1263	1321		

Statistical analyses

Statistical analysis title	All-cause hospitalization
----------------------------	---------------------------

Statistical analysis description:

A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.

Comparison groups	Finerenone v Placebo
Number of subjects included in analysis	5674
Analysis specification	Pre-specified
Analysis type	superiority ^[5]
P-value	= 0.1623 ^[6]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.946

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.876
upper limit	1.022

Notes:

[5] - As treatment effect on both primary and key secondary endpoint was significant, other secondary efficacy endpoints (i.e. all-cause mortality, all-cause hospitalization, change in UACR from baseline to Month 4, and secondary renal composite endpoint) were tested hierarchically, starting with all-cause mortality. As treatment effect on all-cause mortality was not significant, all other endpoints were tested in an exploratory manner.

[6] - P-value from stratified log-rank test.

Secondary: Change in urinary albumin-to-creatinine ratio (UACR) from baseline to Month 4

End point title	Change in urinary albumin-to-creatinine ratio (UACR) from baseline to Month 4
-----------------	---

End point description:

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the subject was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. The analysis was performed on the subjects in FAS with measurements available within the time window of Month 4.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up until Month 4

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2711	2705		
Units: Ratio				
least squares mean (confidence interval 95%)	0.655 (0.637 to 0.673)	0.952 (0.927 to 0.979)		

Statistical analyses

Statistical analysis title	Change in UACR from baseline to Month 4
Comparison groups	Finerenone v Placebo
Number of subjects included in analysis	5416
Analysis specification	Pre-specified
Analysis type	superiority ^[7]
P-value	< 0.0001 ^[8]
Method	ANCOVA
Parameter estimate	Ratio of least squares means
Point estimate	0.688

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.662
upper limit	0.715

Notes:

[7] - As treatment effect on both primary and key secondary endpoint was significant, other secondary efficacy endpoints (i.e. all-cause mortality, all-cause hospitalization, change in UACR from baseline to Month 4, and secondary renal composite endpoint) were tested hierarchically, starting with all-cause mortality. As treatment effect on all-cause mortality was not significant, all other endpoints were tested in an exploratory manner.

[8] - P-value from F-test of equal means between the treatment groups.

Secondary: The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death

End point title	The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death
-----------------	--

End point description:

Count of subjects and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2833	2841		
Units: Subjects				
number (not applicable)	252	326		

Statistical analyses

Statistical analysis title	Secondary renal composite endpoint
-----------------------------------	------------------------------------

Statistical analysis description:

A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.

Comparison groups	Finerenone v Placebo
Number of subjects included in analysis	5674
Analysis specification	Pre-specified
Analysis type	superiority ^[9]
P-value	= 0.0012 ^[10]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.763

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.648
upper limit	0.9

Notes:

[9] - As treatment effect on both primary and key secondary endpoint was significant, other secondary efficacy endpoints (i.e. all-cause mortality, all-cause hospitalization, change in UACR from baseline to Month 4, and secondary renal composite endpoint) were tested hierarchically, starting with all-cause mortality. As treatment effect on all-cause mortality was not significant, all other endpoints were tested in an exploratory manner.

[10] - P-value from stratified log-rank test.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 27 months

Adverse event reporting additional description:

Adverse event reporting for the numbers of deaths (all causes) considers all deaths in the safety analysis set (comprised all randomized subjects who took at least 1 dose of study drug [except those with critical GCP violations]) that occurred at any time during the study after the first dose of study drug (with an average duration of 32 months).

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Finerenone
-----------------------	------------

Reporting group description:

Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received matching placebo once daily in addition to standard of care therapy

Serious adverse events	Finerenone	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	902 / 2827 (31.91%)	971 / 2831 (34.30%)	
number of deaths (all causes)	220	249	
number of deaths resulting from adverse events	31	51	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			

subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenoma benign			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma stage IV			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign salivary gland neoplasm			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	2 / 2827 (0.07%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder squamous cell carcinoma stage unspecified			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	4 / 2827 (0.14%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast neoplasm			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	4 / 2827 (0.14%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon cancer stage IV			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma recurrent			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrosarcoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric cancer			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal carcinoma			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemangioma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypergammaglobulinaemia benign monoclonal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lentigo maligna			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung carcinoma cell type unspecified stage IV			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung squamous cell carcinoma stage IV			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of ampulla of Vater			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver			
subjects affected / exposed	0 / 2827 (0.00%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to lung			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal cavity cancer			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal carcinoma			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal cancer			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pancreatic carcinoma metastatic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Penile cancer			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cancer			

subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small cell lung cancer			
subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superficial spreading melanoma stage unspecified			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage			

unspecified			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer stage 0			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic renal cell carcinoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spleen			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal cancer metastatic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast cancer metastatic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected neoplasm			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer pain			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung neoplasm malignant			

subjects affected / exposed	9 / 2827 (0.32%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 2	
Metastases to central nervous system			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma stage IV			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small cell lung cancer metastatic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer			
subjects affected / exposed	13 / 2827 (0.46%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 13	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Monoclonal gammopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign pancreatic neoplasm			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant urinary tract neoplasm			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland neoplasm			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour benign			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic neoplasm			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung neoplasm			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral neoplasm			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma metastatic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tumour rupture			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatocellular carcinoma			
subjects affected / exposed	3 / 2827 (0.11%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Hepatobiliary cancer			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			

subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiomyofibroblastoma			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma metastatic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure fluctuation			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism venous			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	15 / 2827 (0.53%)	23 / 2831 (0.81%)	
occurrences causally related to treatment / all	0 / 16	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	4 / 2827 (0.14%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	7 / 2827 (0.25%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	3 / 7	2 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intermittent claudication			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 4	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboangiitis obliterans			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			

subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock haemorrhagic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	4 / 2827 (0.14%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			

subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive urgency			
subjects affected / exposed	4 / 2827 (0.14%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous occlusion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microangiopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 2827 (0.00%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			

subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Aortic valve replacement			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation			
subjects affected / exposed	3 / 2827 (0.11%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker insertion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot amputation			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodialysis			

subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
subjects affected / exposed	3 / 2827 (0.11%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hysterectomy			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insertion of ambulatory peritoneal catheter			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	4 / 2827 (0.14%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metatarsal excision			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myomectomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrectomy			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroidectomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Physiotherapy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pterygium operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinoplasty			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal decompression			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenotomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	4 / 2827 (0.14%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral prostatectomy			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia repair			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse repair			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitrectomy			
subjects affected / exposed	1 / 2827 (0.04%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenectomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker replacement			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator insertion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary angioplasty			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fusion surgery			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radical prostatectomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus management			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral bladder resection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac rehabilitation therapy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Continuous positive airway pressure			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephroureterectomy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreaticosplenectomy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polypectomy			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Maxillofacial operation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal transplant			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral dilation procedure			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rehabilitation therapy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dialysis device insertion			

subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin neoplasm excision			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot operation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amputation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthrodesis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colectomy			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye operation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oophorectomy			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatectomy			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric bypass			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele operation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal operation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nail operation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin graft			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal operation			

subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound treatment			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder polypectomy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation			
subjects affected / exposed	4 / 2827 (0.14%)	12 / 2831 (0.42%)	
occurrences causally related to treatment / all	0 / 5	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aneurysm repair			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowel preparation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopexy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular lens implant			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal fixation of spine			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stent removal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric banding reversal			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Therapeutic nerve ablation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery bypass			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal polypectomy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic surgery			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	13 / 2827 (0.46%)	18 / 2831 (0.64%)	
occurrences causally related to treatment / all	0 / 15	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 4	
Fatigue			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothermia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mass			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	4 / 2827 (0.14%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	8 / 2827 (0.28%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue inflammation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swelling face			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia pain			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema due to renal disease			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device intolerance			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Immune system disorders			
Drug hypersensitivity			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Social stay hospitalisation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	5 / 2827 (0.18%)	10 / 2831 (0.35%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysfunctional uterine bleeding			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Uterine haemorrhage			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial thickening			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular mass			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	6 / 2827 (0.21%)	15 / 2831 (0.53%)	
occurrences causally related to treatment / all	0 / 6	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 2	

Aspiration			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	1 / 2827 (0.04%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bronchitis chronic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	14 / 2827 (0.50%)	12 / 2831 (0.42%)	
occurrences causally related to treatment / all	0 / 21	0 / 13	
deaths causally related to treatment / all	0 / 1	0 / 1	
Chronic respiratory failure			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	8 / 2827 (0.28%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 9	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea at rest			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Laryngeal oedema			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal stenosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal oedema			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			

subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	1 / 2827 (0.04%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	8 / 2827 (0.28%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 8	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			

subjects affected / exposed	1 / 2827 (0.04%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	5 / 2827 (0.18%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord polyp			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Restrictive pulmonary disease			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord cyst			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumopathy			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal dysplasia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottic cyst			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal mass			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hilum mass			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Alcohol abuse			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mania			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	4 / 2827 (0.14%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			

subjects affected / exposed	2 / 2827 (0.07%)	9 / 2831 (0.32%)	
occurrences causally related to treatment / all	0 / 2	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	12 / 2827 (0.42%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 14	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	1 / 2827 (0.04%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic function abnormal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis alcoholic			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dilatation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic lesion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy kidney			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 2827 (0.04%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 1	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonoscopy			

subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endoscopy small intestine			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerular filtration rate decreased			
subjects affected / exposed	5 / 2827 (0.18%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 5	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Protein urine present			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker evaluation			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Computerised tomogram abdomen			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Light chain analysis increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level above therapeutic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammatory marker increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular examination			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arteriogram			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiocardiogram			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			

subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	7 / 2827 (0.25%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back injury			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dislocation of vertebra			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	2 / 2827 (0.07%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	7 / 2827 (0.25%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	6 / 2827 (0.21%)	9 / 2831 (0.32%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat stroke			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	6 / 2827 (0.21%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Humerus fracture			
subjects affected / exposed	4 / 2827 (0.14%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning deliberate			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation proctitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	5 / 2827 (0.18%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue injury			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury cervical			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Spinal fracture			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	4 / 2827 (0.14%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tendon injury			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			

subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic fracture			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation of wound			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula site complication			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post concussion syndrome			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site haematoma			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament injury			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	4 / 2827 (0.14%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt malfunction			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural inflammation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wound dehiscence			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac contusion			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemothorax			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated incisional hernia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access malfunction			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular procedural complication			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Dermoid cyst			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Factor VIII deficiency			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phimosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Truncus arteriosus persistent			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	0 / 2827 (0.00%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			

subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	1 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac asthma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 2827 (0.04%)	10 / 2831 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			

subjects affected / exposed	0 / 2827 (0.00%)	8 / 2831 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiogenic shock			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	8 / 2827 (0.28%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 2827 (0.00%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			

subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve calcification			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute coronary syndrome			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bifascicular block			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve disease			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiorenal syndrome			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic mitral regurgitation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Alcohol induced persisting dementia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brown-Sequard syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular disorder			
subjects affected / exposed	4 / 2827 (0.14%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve palsies multiple			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	6 / 2827 (0.21%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	6 / 2827 (0.21%)	10 / 2831 (0.35%)	
occurrences causally related to treatment / all	0 / 6	2 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drop attacks			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			

subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post herpetic neuralgia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	4 / 2827 (0.14%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Syncope			

subjects affected / exposed	12 / 2827 (0.42%)	22 / 2831 (0.78%)	
occurrences causally related to treatment / all	0 / 12	2 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Carotid artery occlusion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery occlusion			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arachnoid cyst			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			

subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurodegenerative disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroglycopenia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral vasoconstriction			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mononeuropathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral arteriosclerosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic cerebral infarction			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral microangiopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia with Lewy bodies			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Secondary cerebellar degeneration			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral vascular occlusion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post stroke epilepsy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianaesthesia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiopathic neuropathy			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	14 / 2827 (0.50%)	19 / 2831 (0.67%)	
occurrences causally related to treatment / all	0 / 14	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	5 / 2827 (0.18%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrogenic anaemia			
subjects affected / exposed	0 / 2827 (0.00%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood loss anaemia			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Deafness neurosensory			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear pain			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane perforation			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			

subjects affected / exposed	3 / 2827 (0.11%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness unilateral			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Blindness			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	19 / 2827 (0.67%)	12 / 2831 (0.42%)	
occurrences causally related to treatment / all	0 / 22	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract diabetic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract subcapsular			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinal oedema			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	3 / 2827 (0.11%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ectropion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorder			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	6 / 2827 (0.21%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 10	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lens dislocation			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open angle glaucoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic disc haemorrhage			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papilloedema			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pterygium			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	4 / 2827 (0.14%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	6 / 2827 (0.21%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular hole			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhegmatogenous retinal detachment			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tractional retinal detachment			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	6 / 2827 (0.21%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Change of bowel habit			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			

subjects affected / exposed	3 / 2827 (0.11%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental caries			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	7 / 2827 (0.25%)	6 / 2831 (0.21%)	
occurrences causally related to treatment / all	1 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea haemorrhagic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal polyp			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			

subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Duodenal ulcer perforation			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Duodenitis haemorrhagic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenal ulcer			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			

subjects affected / exposed	13 / 2827 (0.46%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 16	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal necrosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 2827 (0.04%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal angina			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal achalasia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic cyst			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	7 / 2827 (0.25%)	8 / 2831 (0.28%)	
occurrences causally related to treatment / all	1 / 8	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	6 / 2827 (0.21%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland calculus			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	2 / 2827 (0.07%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vomiting			
subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	6 / 2827 (0.21%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			

subjects affected / exposed	5 / 2827 (0.18%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chilaiditi's syndrome			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedematous pancreatitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal strangulated hernia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer haemorrhage			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholic pancreatitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric mucosal lesion			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic duct stenosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Functional gastrointestinal disorder			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal mass			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated umbilical hernia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal fluid collection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal vascular malformation haemorrhagic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angioedema			

subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blister			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis bullous			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis herpetiformis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ecchymosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkeratosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ingrowing nail			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parapsoriasis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Purpura			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin disorder			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	9 / 2827 (0.32%)	16 / 2831 (0.57%)	
occurrences causally related to treatment / all	0 / 10	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic ulcer			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	13 / 2827 (0.46%)	18 / 2831 (0.64%)	
occurrences causally related to treatment / all	0 / 16	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Azotaemia			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Calculus bladder			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chromaturia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis ulcerative			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysuria			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerular vascular disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	3 / 2827 (0.11%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intercapillary glomerulosclerosis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	6 / 2827 (0.21%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrosclerosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	3 / 2827 (0.11%)	9 / 2831 (0.32%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocturia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			

subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	7 / 2827 (0.25%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	2 / 7	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haemorrhage			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular acidosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			

subjects affected / exposed	6 / 2827 (0.21%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder polyp			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cyst			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	18 / 2827 (0.64%)	16 / 2831 (0.57%)	
occurrences causally related to treatment / all	0 / 23	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			

subjects affected / exposed	8 / 2827 (0.28%)	8 / 2831 (0.28%)	
occurrences causally related to treatment / all	0 / 8	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	12 / 2827 (0.42%)	22 / 2831 (0.78%)	
occurrences causally related to treatment / all	1 / 12	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	56 / 2827 (1.98%)	51 / 2831 (1.80%)	
occurrences causally related to treatment / all	10 / 63	6 / 55	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bladder outlet obstruction			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephritis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	5 / 2827 (0.18%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 5	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcapsular renal haematoma			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary-dependent Cushing's syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid mass			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 2827 (0.00%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Back disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	3 / 2827 (0.11%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	5 / 2827 (0.18%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	4 / 2827 (0.14%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	11 / 2827 (0.39%)	8 / 2831 (0.28%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthropathy			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			

subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	7 / 2827 (0.25%)	13 / 2831 (0.46%)	
occurrences causally related to treatment / all	0 / 7	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma muscle			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Connective tissue inflammation			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis of jaw			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue necrosis			

subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal instability			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb mass			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	9 / 2827 (0.32%)	13 / 2831 (0.46%)	
occurrences causally related to treatment / all	0 / 9	1 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	26 / 2827 (0.92%)	22 / 2831 (0.78%)	
occurrences causally related to treatment / all	0 / 30	0 / 23	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	3 / 2827 (0.11%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endophthalmitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 2827 (0.04%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			

subjects affected / exposed	11 / 2827 (0.39%)	14 / 2831 (0.49%)	
occurrences causally related to treatment / all	0 / 11	0 / 16	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fournier's gangrene			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	5 / 2827 (0.18%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastroenteritis			
subjects affected / exposed	9 / 2827 (0.32%)	13 / 2831 (0.46%)	
occurrences causally related to treatment / all	0 / 9	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis viral			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	4 / 2827 (0.14%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	1 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	7 / 2827 (0.25%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Labyrinthitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leptospirosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	2 / 2827 (0.07%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			

subjects affected / exposed	7 / 2827 (0.25%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	5 / 2827 (0.18%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	14 / 2827 (0.50%)	12 / 2831 (0.42%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteomyelitis chronic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis streptococcal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	70 / 2827 (2.48%)	103 / 2831 (3.64%)	
occurrences causally related to treatment / all	0 / 75	0 / 115	
deaths causally related to treatment / all	0 / 1	0 / 5	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pyelonephritis			
subjects affected / exposed	7 / 2827 (0.25%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	5 / 2827 (0.18%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyonephrosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal abscess			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			

subjects affected / exposed	15 / 2827 (0.53%)	17 / 2831 (0.60%)	
occurrences causally related to treatment / all	0 / 15	0 / 18	
deaths causally related to treatment / all	0 / 1	0 / 3	
Septic shock			
subjects affected / exposed	3 / 2827 (0.11%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 4	
Sinusitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic abscess			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 2827 (0.00%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethritis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	21 / 2827 (0.74%)	23 / 2831 (0.81%)	
occurrences causally related to treatment / all	0 / 22	0 / 30	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral pericarditis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral tracheitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	4 / 2827 (0.14%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral infection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	5 / 2827 (0.18%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelocystitis			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillitis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	3 / 2827 (0.11%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burn infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma infection			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest wall abscess			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	5 / 2827 (0.18%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	3 / 2827 (0.11%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal tuberculosis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			

subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis infectious			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viraemia			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis B			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	4 / 2827 (0.14%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			

subjects affected / exposed	2 / 2827 (0.07%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	1 / 2827 (0.04%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Borrelia infection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes ophthalmic			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection staphylococcal			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			

subjects affected / exposed	3 / 2827 (0.11%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective spondylitis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stoma site infection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermo-hypodermatitis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural sepsis			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of bronchiectasis			

subjects affected / exposed	0 / 2827 (0.00%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected seroma			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site joint infection			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected bite			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephritis bacterial			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bullous erysipelas			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	7 / 2827 (0.25%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	1 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			

subjects affected / exposed	10 / 2827 (0.35%)	16 / 2831 (0.57%)	
occurrences causally related to treatment / all	0 / 12	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	12 / 2827 (0.42%)	19 / 2831 (0.67%)	
occurrences causally related to treatment / all	0 / 13	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	7 / 2827 (0.25%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	7 / 2827 (0.25%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	1 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	2 / 2827 (0.07%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	1 / 2827 (0.04%)	7 / 2831 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	17 / 2827 (0.60%)	23 / 2831 (0.81%)	
occurrences causally related to treatment / all	0 / 20	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	42 / 2827 (1.49%)	12 / 2831 (0.42%)	
occurrences causally related to treatment / all	26 / 45	5 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperosmolar state			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypervolaemia			
subjects affected / exposed	2 / 2827 (0.07%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	21 / 2827 (0.74%)	31 / 2831 (1.10%)	
occurrences causally related to treatment / all	0 / 23	0 / 33	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia unawareness			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	3 / 2827 (0.11%)	5 / 2831 (0.18%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			

subjects affected / exposed	8 / 2827 (0.28%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	1 / 12	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoproteinaemia			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	3 / 2827 (0.11%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	1 / 2827 (0.04%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	2 / 2827 (0.07%)	3 / 2831 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour lysis syndrome			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calciphylaxis			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic disorder			
subjects affected / exposed	0 / 2827 (0.00%)	1 / 2831 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic complication			

subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 2827 (0.04%)	0 / 2831 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	0 / 2827 (0.00%)	2 / 2831 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	2 / 2827 (0.07%)	4 / 2831 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	14 / 2827 (0.50%)	22 / 2831 (0.78%)	
occurrences causally related to treatment / all	0 / 16	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic metabolic decompensation			
subjects affected / exposed	12 / 2827 (0.42%)	14 / 2831 (0.49%)	
occurrences causally related to treatment / all	0 / 15	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Finerenone	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1602 / 2827 (56.67%)	1584 / 2831 (55.95%)	
Investigations			
Glomerular filtration rate decreased			
subjects affected / exposed	177 / 2827 (6.26%)	130 / 2831 (4.59%)	
occurrences (all)	225	146	

Vascular disorders Hypertension subjects affected / exposed occurrences (all)	200 / 2827 (7.07%) 229	262 / 2831 (9.25%) 323	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	143 / 2827 (5.06%) 165	147 / 2831 (5.19%) 162	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	201 / 2827 (7.11%) 218	177 / 2831 (6.25%) 196	
General disorders and administration site conditions Oedema peripheral subjects affected / exposed occurrences (all)	183 / 2827 (6.47%) 216	303 / 2831 (10.70%) 359	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all)	128 / 2827 (4.53%) 146 183 / 2827 (6.47%) 216	162 / 2831 (5.72%) 179 188 / 2831 (6.64%) 224	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all)	142 / 2827 (5.02%) 163 175 / 2827 (6.19%) 187	145 / 2831 (5.12%) 157 170 / 2831 (6.00%) 182	
Infections and infestations Bronchitis subjects affected / exposed occurrences (all) Nasopharyngitis subjects affected / exposed occurrences (all)	127 / 2827 (4.49%) 140 241 / 2827 (8.52%) 368	142 / 2831 (5.02%) 188 250 / 2831 (8.83%) 391	

Upper respiratory tract infection subjects affected / exposed occurrences (all)	181 / 2827 (6.40%) 274	185 / 2831 (6.53%) 262	
Urinary tract infection subjects affected / exposed occurrences (all)	168 / 2827 (5.94%) 215	185 / 2831 (6.53%) 259	
Metabolism and nutrition disorders			
Hyperkalaemia subjects affected / exposed occurrences (all)	422 / 2827 (14.93%) 634	212 / 2831 (7.49%) 281	
Hypoglycaemia subjects affected / exposed occurrences (all)	137 / 2827 (4.85%) 212	173 / 2831 (6.11%) 299	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 May 2017	The major modifications specified in Amendment 3 were an increase of study duration and site numbers to account for lower than expected recruitment rate, amended re-screening rules, a modification of an exclusion criterion to allow randomization of subjects with a recent CV disease episode, and the addition of the definition of the endpoint "kidney failure".
26 February 2019	The main modification due to Amendment 4 was to allow performing the post-treatment Visit as a telephone contact, to specify baseline values for subjects who did not immediately start with study drug treatment, to increase the time window after last study drug administration from 3 to 30 days for on-treatment analyses to better reflect the more protracted nature of the development and diagnosis of clinical outcome events of interest in relation to treatment exposure, and to specify the definition of treatment emergent AEs and interruptions of study treatment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31655812>

<http://www.ncbi.nlm.nih.gov/pubmed/33264825>

<http://www.ncbi.nlm.nih.gov/pubmed/33198491>